The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note that we have added three critical tables, which are continuously updated:
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acurx, Cerevance, Foresee, Galderma, Genentech, Gilead, Karolinska, Merck, Mitsubishi Tanabe, Novo Nordisk, Nurix, Regeneron, Regenxbio, Roche.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alnylam, Astria, GSK, ipsen, Novavax, Theriva, Tonix, Urogen.
Shares of Novavax Inc. (NASDAQ:NVAX) dropped nearly 20% Oct. 16 to close at $10.15 after the company reported a serious adverse event had prompted a U.S. FDA clinical hold for its COVID-19-influenza combination and standalone flu vaccine candidates.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aurigene, Clearside, Dyne, Entrada, Innocare, Insmed, Panavance, Tevogen, Vanqua, Viatris, Viking.
The COVID-19 pandemic pushed the urgency for effective antiviral drugs against coronaviruses. Researchers from Europe conducted machine learning and in vitro validation experiments for the identification of potential antiviral drugs effective against coronaviruses.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abivax, Ennodc, Expert Systems, Irlab, Theriva, Trawsfynydd.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Biotheus, Eliem, Emergex, Frazier, Gilead, Immunoprecise, Intelgenx, J&J, Novaliq, Verrica.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Astrazeneca, Bpgbio, Clinuvel, Daiichi, Formycon, Fresenius, Invivyd, Ionis, J&J, Oryzon, Papillon, PTC, Sagimet, Thryv.
RSS
